CEL-SCI Corporation (CVM)

In the past six months, CEL-SCI Corp. has experienced several notable stock events. CEL-SCI reported its fiscal second-quarter 2025 financial results. The company implemented a 1-for-30 stock split to support its share price and completed a follow-on equity offering of $5 million. CEL-SCI announced a $5.7 million public offering, which sparked discussions among investors regarding potential share dilution. CEL-SCI reported Q3 EPS of ($1.36) versus ($4.18) in the prior year. The company announced and closed a $10 million public offering, with shares priced at a discount, leading to a stock price fall. CEL-SCI extended its Shareholder Rights Agreement to 2030 and filed to sell 375,000 shares of common stock for holders. The stock price has shown an increase of 15.36% compared to the previous week, but a fall of -18.10% over the month. Over the past six months, CVM has trended up by 199.20%.

As a clinical-stage biotechnology company, there is no readily available information to suggest inherent demand seasonality for CEL-SCI Corp.'s products and services. The company's revenue generation is not yet tied to commercial product sales that would typically exhibit seasonal demand patterns. Stock price seasonality tools exist for CVM, but these relate to market trends rather than the demand for the company's specific therapeutic products.

CEL-SCI Corp. is a clinical-stage biotechnology company focused on immunotherapy products for cancer, autoimmune, and infectious diseases. Its primary mission is to utilize the immune system to combat diseases, with its flagship drug, Multikine, completing Phase III trials for head and neck cancers. CEL-SCI is also developing the LEAPS technology, a T-cell modulation process aimed at stimulating the immune system to fight various conditions, with product candidates in preclinical trials for rheumatoid arthritis and having explored applications for influenza and COVID-19.

CEL-SCI Corp. is headquartered in Vienna, Virginia, United States. The company is actively focused on expanding its international presence, seeking regulatory approvals in regions such as Europe, Asia, and Latin America. It also has a strategic partnership with Saudi Arabian Pharma Company for Multikine in the treatment of head and neck cancer.

In the past year, CEL-SCI's brand reputation has been influenced by developments related to Multikine and corporate governance. A study validated CEL-SCI's approach to seeking early approval for Multikine, which could positively impact its scientific and medical reputation. The company's commitment to ethical practices in clinical research and manufacturing is also a stated aspect of its operations. Revisions to its Shareholder Rights Agreement aim to strengthen corporate governance and shareholder protections. Discussions on social media platforms regarding a public offering showed a mixed sentiment, with some investors expressing concerns about potential share dilution.

The ownership structure of CEL-SCI is a mix of institutional, retail, and individual investors. Approximately 2.67% to 12.08% of the company's stock is held by institutional investors, with major holders including Vanguard Group Inc. and BlackRock, Inc. Insiders hold approximately 1.26% to 2.04% of the stock, with CEO Geert R. Kersten being a notable insider. The general public and individual investors hold a significant portion, estimated to be around 80.7% to 92.22% of the shares.